PL2252893T3 - Sposób wczesnego określenia nawrotu po leczeniu nowotworu gruczołu krokowego - Google Patents

Sposób wczesnego określenia nawrotu po leczeniu nowotworu gruczołu krokowego

Info

Publication number
PL2252893T3
PL2252893T3 PL09713301T PL09713301T PL2252893T3 PL 2252893 T3 PL2252893 T3 PL 2252893T3 PL 09713301 T PL09713301 T PL 09713301T PL 09713301 T PL09713301 T PL 09713301T PL 2252893 T3 PL2252893 T3 PL 2252893T3
Authority
PL
Poland
Prior art keywords
recurrence
therapy
prostate cancer
early determination
early
Prior art date
Application number
PL09713301T
Other languages
English (en)
Inventor
Mark J Sarno
Robert E Klem
Russ Saunders
Edward Jablonski
Thomas Adams
Original Assignee
Iris Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iris Int Inc filed Critical Iris Int Inc
Publication of PL2252893T3 publication Critical patent/PL2252893T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL09713301T 2008-02-21 2009-02-19 Sposób wczesnego określenia nawrotu po leczeniu nowotworu gruczołu krokowego PL2252893T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6673208P 2008-02-21 2008-02-21
US3046208P 2008-02-21 2008-02-21
US3071808P 2008-02-22 2008-02-22
PCT/US2009/001114 WO2009105264A1 (en) 2008-02-21 2009-02-19 Method for early determination of recurrence after therapy for prostate cancer
EP09713301.1A EP2252893B1 (en) 2008-02-21 2009-02-19 Method for early determination of recurrence after therapy for prostate cancer

Publications (1)

Publication Number Publication Date
PL2252893T3 true PL2252893T3 (pl) 2014-03-31

Family

ID=40481886

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09713301T PL2252893T3 (pl) 2008-02-21 2009-02-19 Sposób wczesnego określenia nawrotu po leczeniu nowotworu gruczołu krokowego

Country Status (10)

Country Link
US (2) US20090246781A1 (pl)
EP (2) EP2623985A1 (pl)
JP (1) JP5808538B2 (pl)
KR (1) KR20100122932A (pl)
CN (2) CN102016588B (pl)
AU (1) AU2009215799B2 (pl)
CA (1) CA2716027A1 (pl)
ES (1) ES2433745T3 (pl)
PL (1) PL2252893T3 (pl)
WO (1) WO2009105264A1 (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2290100B1 (en) * 2002-11-01 2014-02-19 Iris International, Inc. Kits for displacement Sandwich Immuno-PCR
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
DE602005023529D1 (de) * 2004-11-03 2010-10-21 Iris Molecular Diagnostics Inc Homogener nachweis von analyten
JP5037350B2 (ja) 2004-11-03 2012-09-26 アイリス モレキュラー ダイアグノスティクス， インコーポレイテッド 親和性分離のための微粒気泡
WO2011116209A2 (en) 2010-03-17 2011-09-22 The Regents Of The University Of Michigan Using phage epitopes to profile the immune response
US20140227720A1 (en) * 2011-06-09 2014-08-14 Quanterix Corporation Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
GB2505266A (en) * 2012-04-09 2014-02-26 Soar Biodynamics Ltd Estimating the probability of a prostate condition by dynamic analysis
US20130323739A1 (en) * 2012-06-05 2013-12-05 Iris International, Inc. Method for determining recurrence or stable disease after treatment for prostate cancer
US10745760B2 (en) 2014-01-17 2020-08-18 University Health Network Biopsy-driven genomic signature for prostate cancer prognosis
WO2017027643A1 (en) 2015-08-10 2017-02-16 Essenlix Corp. Bio/chemical assay devices and methods for simplified steps, small samples, accelerated speed, and ease-of-use
KR20190057445A (ko) 2015-09-14 2019-05-28 에센릭스 코프. 샘플 특히 혈액샘플을 분석하기 위한 장치와 시스템 및 그 사용 방법
HK1254027A1 (zh) 2015-09-14 2019-07-12 Essenlix Corporation 采集分析蒸汽凝析，特别是呼出气凝析的装置与系统，以及使用方法
JPWO2018101328A1 (ja) * 2016-11-29 2019-10-24 コニカミノルタ株式会社 診療補助情報の取得方法
EP3558121B1 (en) 2016-12-21 2022-06-08 Essenlix Corporation Devices and methods for authenticating a sample and use of the same
EP3579981A4 (en) 2017-02-07 2021-03-31 Essenlix Corporation COMPRESSED OPEN FLOW TEST AND USE
CA3052809A1 (en) 2017-02-08 2018-08-23 Essenlix Corporation Qmax assays and applications
WO2018148469A1 (en) 2017-02-08 2018-08-16 Essenlix Corp. Bio/chemical material extraction and assay
CN110741240A (zh) 2017-02-08 2020-01-31 Essenlix公司 通过控制温度的分子操作和检测
CA3053005A1 (en) 2017-02-08 2018-08-16 Essenlix Corporation Sample collection and handling for delayed analysis
CA3053114A1 (en) 2017-02-09 2018-08-16 Essenlix Corporation Assay using different spacing heights
CN110998325B (zh) 2017-02-09 2024-08-16 上海宜晟生物科技有限公司 扩增测定
JP2020507770A (ja) 2017-02-09 2020-03-12 エッセンリックス コーポレーション 比色アッセイ法
EP3583423A4 (en) 2017-02-15 2021-03-31 Essenlix Corporation QUICK TEMPERATURE CHANGE DOSAGE
CA3053301A1 (en) 2017-02-16 2018-08-23 Essenlix Corporation Assay with textured surface
CN108959839A (zh) * 2017-05-26 2018-12-07 长沙金域医学检验所有限公司 一种生化发光功能灵敏度评估方法
JP7339245B2 (ja) 2017-06-12 2023-09-05 エッセンリックス コーポレーション 均質アッセイ法
US11280706B2 (en) 2017-08-01 2022-03-22 Essenlix Corporation Dilution calibration
CN111492222A (zh) 2017-08-01 2020-08-04 Essenlix公司 样品收集、保持和测定
WO2019028133A1 (en) 2017-08-01 2019-02-07 Essenlix Corporation Devices and methods for examining drug effects on microorganisms
WO2019075244A1 (en) 2017-10-11 2019-04-18 Essenlix Corporation CONTAINING A LIQUID SAMPLE
WO2019075415A1 (en) 2017-10-13 2019-04-18 Essenlix Corporation DEVICES AND METHODS FOR AUTHENTICATING MEDICAL ANALYSIS AND USES THEREOF
US11609224B2 (en) 2017-10-26 2023-03-21 Essenlix Corporation Devices and methods for white blood cell analyses
US11237113B2 (en) 2017-10-26 2022-02-01 Essenlix Corporation Rapid pH measurement
US10807095B2 (en) 2017-10-26 2020-10-20 Essenlix Corporation Making and tracking assay card
WO2019118652A1 (en) 2017-12-12 2019-06-20 Essenlix Corporation Sample manipulation and assay with rapid temperature change
US11510608B2 (en) 2017-12-14 2022-11-29 Essenlix Corporation Devices, systems, and methods for monitoring hair
US11156606B2 (en) 2018-01-11 2021-10-26 Essenlix Corporation Homogeneous assay (II)
US11885952B2 (en) 2018-07-30 2024-01-30 Essenlix Corporation Optics, device, and system for assaying and imaging
US20230005594A1 (en) * 2019-12-06 2023-01-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Clinical decision support for personalized adaptive prostate cancer therapy

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1582956A (en) * 1976-07-30 1981-01-21 Ici Ltd Composite magnetic particles
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
FR2571498B1 (fr) * 1984-10-04 1988-04-08 Immunotech Sa Procede de separation de cellules utilisant des anticorps et des billes de faible densite
US4618525A (en) * 1985-06-03 1986-10-21 Minnesota Mining And Manufacturing Company Coated glass microbubbles and article incorporating them
US4824776A (en) * 1985-07-25 1989-04-25 Molecular Biosystems, Inc. Method for increasing the sensitivity of nucleic acid hybridization assays
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4933447A (en) * 1987-09-24 1990-06-12 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5766849A (en) * 1989-07-11 1998-06-16 Gen-Probe Incorporated Methods of amplifying nucleic acids using promoter-containing primer sequence
SE9002480D0 (sv) * 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
EP0529070A1 (en) * 1991-02-27 1993-03-03 Amoco Corporation Methods for improving the sensitivity of hybridization assays
US5665539A (en) 1991-07-12 1997-09-09 The Regents Of The University Of California Immuno-polymerase chain reaction system for antigen detection
US6723303B1 (en) * 1991-09-17 2004-04-20 Amersham Health, As Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane
US5270184A (en) * 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
US6172208B1 (en) * 1992-07-06 2001-01-09 Genzyme Corporation Oligonucleotides modified with conjugate groups
JP3778925B2 (ja) * 1993-01-15 2006-05-24 ザ パブリック ヘルス リサーチ インスティチュート オブ ザ シティー オブ ニューヨーク インク 高感度核酸サンドイッチハイブリダイゼーション検定法及びキット
US5985548A (en) * 1993-02-04 1999-11-16 E. I. Du Pont De Nemours And Company Amplification of assay reporters by nucleic acid replication
DE69432897T2 (de) * 1993-05-10 2004-05-27 Nissui Pharmaceutical Co., Ltd. Verfahren zur bestimmung von mehr als einem immunologischen liganden und bestimmungsreagenz sowie satz dafuer
US5635602A (en) * 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
US5599677A (en) * 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5648213A (en) * 1994-08-30 1997-07-15 Beckman Instruments, Inc. Compositions and methods for use in detection of analytes
JPH08178926A (ja) * 1994-10-25 1996-07-12 Sumitomo Pharmaceut Co Ltd イムノアッセイプレートおよびその用途
DE19524133A1 (de) * 1995-07-03 1997-01-09 Bayer Ag Die Verwendung von neuen und bekannten kationischen 4,5-Dihydro-1H-1,2,3-triazoliumverbindungen als Farbstoffe, neue kationische 4,5-Dihydro-1H-1,2,3-triazoliumverbindungen und deren Herstellung
US6165942A (en) * 1996-10-03 2000-12-26 Nissan Chemical Industries, Ltd. Heterocycle-fused pyrimidinone derivative and herbicidal composition
US6083484A (en) * 1996-10-17 2000-07-04 Molecular Biosystems, Inc. Microparticles stabilized by polynuclear chromium complexes and their use as ultrasound contrast agents
US6245318B1 (en) * 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
US6086540A (en) * 1997-10-07 2000-07-11 Molecular Biosystems, Inc. Methods of ultrasound imaging using echogenically persistent contrast agents
US6531278B1 (en) * 1998-01-14 2003-03-11 Utah State University Ligand-DNA composition for capture and detection of contaminants on a solid surface
DE69916822T2 (de) * 1998-04-28 2005-04-21 Amersham Health As Oslo Verbesserung von trennungsverfahren
US8063190B2 (en) * 1998-06-02 2011-11-22 Tom Robin Caine Boyde Nucleic acid-linked conjugates and methods for making and using them
US6214566B1 (en) * 1998-11-16 2001-04-10 The Administrators Of The Tulane Educational Fund Method for detecting anti-squalene antibodies
AU7896700A (en) * 1999-10-13 2001-04-23 University Of British Columbia, The Methods to identify compounds that modulate neuronal activity
CA2391534A1 (en) * 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
US7306904B2 (en) * 2000-02-18 2007-12-11 Olink Ab Methods and kits for proximity probing
US6511809B2 (en) * 2000-06-13 2003-01-28 E. I. Du Pont De Nemours And Company Method for the detection of an analyte by means of a nucleic acid reporter
AU2001268481A1 (en) * 2000-06-15 2001-12-24 Board Of Regents, The University Of Texas System Regulatable, catalytically active nucleic acids
WO2002068695A2 (en) * 2001-02-22 2002-09-06 Arcturus Engineering, Inc. Quantitative immunohistochemistry (qihc)
SE0103839D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
CN1871517A (zh) * 2002-02-19 2006-11-29 免疫公司 快速有效分离循环癌细胞的方法和试剂
JP2003238443A (ja) * 2002-02-20 2003-08-27 Teikoku Hormone Mfg Co Ltd 前立腺毛細血管萎縮剤
CA2872136C (en) * 2002-07-18 2017-06-20 Merus B.V. Recombinant production of mixtures of antibodies
US7649001B2 (en) * 2002-08-12 2010-01-19 Takeda Pharmaceutical Company Limited Fused benzene derivative and use
EP2290100B1 (en) * 2002-11-01 2014-02-19 Iris International, Inc. Kits for displacement Sandwich Immuno-PCR
US20090176207A1 (en) * 2004-06-23 2009-07-09 Washington University Methods for Determining Risk of Developing Regular Smoking Behavior
DE602005023529D1 (de) * 2004-11-03 2010-10-21 Iris Molecular Diagnostics Inc Homogener nachweis von analyten
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
JP4692200B2 (ja) * 2005-10-06 2011-06-01 横河電機株式会社 化学処理用カートリッジおよびその使用方法
CN101566626A (zh) * 2008-07-22 2009-10-28 深圳市人民医院 一种抗原检测方法及其应用

Also Published As

Publication number Publication date
JP2011513705A (ja) 2011-04-28
AU2009215799B2 (en) 2013-08-22
CN103884840A (zh) 2014-06-25
WO2009105264A1 (en) 2009-08-27
ES2433745T3 (es) 2013-12-12
CN102016588B (zh) 2014-05-14
US20130224752A1 (en) 2013-08-29
CA2716027A1 (en) 2009-08-27
EP2252893A1 (en) 2010-11-24
EP2623985A1 (en) 2013-08-07
US20090246781A1 (en) 2009-10-01
AU2009215799A1 (en) 2009-08-27
EP2252893B1 (en) 2013-10-23
CN102016588A (zh) 2011-04-13
KR20100122932A (ko) 2010-11-23
JP5808538B2 (ja) 2015-11-10

Similar Documents

Publication Publication Date Title
PL2252893T3 (pl) Sposób wczesnego określenia nawrotu po leczeniu nowotworu gruczołu krokowego
IL251403A0 (en) A method for using gene expression to determine the prognosis of prostate cancer
IL216913A0 (en) Targeted nano-photomedicines for photodynamic therapy of cancer
ZA201207229B (en) Method for breast cancer recurrence prediction under endocrine treatment
IL215767A0 (en) Methods of treatment for solid tumors
ZA200906764B (en) Methods of treating cancer using pyridopyrimidinone inhibitors of P13K alpha
ZA201200408B (en) Biomarkers amd methods for determining efficacy of anti-egfr antibodies in cancer therapy
EP2461814A4 (en) PROSTATE CANCER TREATMENT
PT2207037T (pt) Método para a deteção de cancro
IL200197A (en) A method for assessing prostate cancer risk by determining genetic variants
ZA201107879B (en) Composition for the treatment of prostate cancer
EP2373794A4 (en) NECTINE-4 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS OF CANCER
EP2367939A4 (en) METHODS FOR THE DIAGNOSIS OR TREATMENT OF PROSTATE CANCER
IL196208A0 (en) Methods for cancer treatment using tak1 inhibitors
EP2280078A4 (en) MARKER FOR DETERMINING BREAST CANCER, TEST METHOD, AND TEST KIT
ZA201103627B (en) Prophylactic/therapeutic agent for cancer
EP2195425A4 (en) PKIB AND NAALADL2 FOR TARGET GENES OF THERAPY AND DIAGNOSIS OF PROSTATE CANCER
IL222167A (en) Genetic prediction of psa recurrence for patients with cancer clinically located in the prostate
IL218230A0 (en) Method of treating cancer
ZA201109508B (en) Methods of using corticotropin-releasing factor for the treatment of cancer
PL2608802T3 (pl) Immunoterapeutyczny sposób leczenia raka gruczołu krokowego
SMT201700231T1 (it) Inibitori del proteasoma per il trattamento di cancro
EP2560639A4 (en) METHOD FOR THE TREATMENT OF PROSTATE CANCER
EP2350276A4 (en) SYNGR4 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS
EP2278025A4 (en) METHOD FOR ASSESSING DEGREE OF MALIGNANCY OF TUMOR CELL